Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC; A retrospective analysis shows that trifluridine/tipiracil with or without bevacizumab given biweekly was favorable in those with colorectal cancer.

Media coverage

• Title	Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC; A retrospective analysis shows that trifluridine/tipiracil with or without bevacizumab given biweekly was favorable in those with colorectal cancer.
  Media name/outlet	CancerNetwork
  Country/Territory	United States
  Date	06/17/25
  Persons	Christopher G. Cann

• Title	Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC
  Media name/outlet	Cancernetwork.com
  Country/Territory	United States
  Date	06/17/25
  URL	https://www.cancernetwork.com/view/biweekly-tas-102-reduces-toxicity-maintains-survival-in-metastatic-crc
  Persons	Christopher G. Cann